...A. There are 600,000 patients in the US today, roughly 80% of those patients are not receiving a VMAT2 inhibitor. B. And I start there because in Q2, we reported $580 million of revenue. C. That's over 30% year-to-year growth about 15% quarter-on-quarter growth. D. And that was all driven by increased demand for the product with strong demand in terms of the patients that are out there as well as some improvements in gross to net, but we also saw let's raise our guidance to $2.2 billion to $2.3 billion, which is about a 25% per year growth at the midpoint. E. If you combined where we are over $2 billion of revenue with the significant growth that's still available out there for patients to receive treatment and a long-dated LOE out to 2038. F. That's our AMPA-PAM for MDD and other is NBI-568, this is our selective M4 agonist that we have in development for schizophrenia with positive Phase 2 trials, those will move into Phase 3 next year and a couple of years. G. This is an MDA in our 2b...
